



Article Title

First Author^{1,*}, Co-Author² and Co-Author²

¹Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

²Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

Correspondence*:

corresponding Author

Laboratory X, Institute X, Department X, Organization X, Street X, City X, State XX (only USA, Canada and Australia), Zip Code, X Country X, email@uni.edu

Research Topic

2 ABSTRACT

3 See the Summary Table at

4 <http://www.frontiersin.org/Bioengineering/authorguidelines>
5 for abstract requirement and length according to article type.

6 **Keywords:** Text Text Text Text Text Text Text Text

1 INTRODUCTION

7 Text
8 Text. Text
9 Text. Text
10 Text. Text
11 Text.

2 MATERIAL & METHODS

12 Text
13 Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text. **LastName1 et al.** (2013) might want to know
14 about text text text text Text Text Text Text Text Text Text Text Text Text Text. (**OtherAuthor and**
15 **Coauthor**, 2012) might want to know about text text text text Text Text Text Text Text Text Text Text Text Text
16 Text
17 Text Text Text. **Author4 and Author5** (2013) might want to know about text text text text

2.1 ORIGINAL RESEARCH ARTICLES, CLINICAL TRIAL ARTICLES, AND TECHNOLOGY REPORTS

18 For Original Research Articles, Clinical Trial Articles, and Technology Reports the following sections are
19 mandatory:

Table 1. Resolution Requirements for the figures

Image Type	Description	Format	Color Mode	Resolution
Line Art	An image composed of lines and text, which does not contain tonal or shaded areas.	TIFF, EPS, JPEG	RGB, Bitmap	900 - 1200 dpi
Halftone	A continuous tone photograph, which contains no text.	TIFF, EPS, JPEG	RGB, Grayscale	300 dpi
Combination	Image contains halftone + text or line art elements.	TIFF, EPS, JPEG	RGB, Grayscale	600 - 900 dpi

This is a footnote

- 20 • Introduction: Succinct, with no subheadings.
- 21 • Materials and Methods: This section may be divided by subheadings. This section should contain
- 22 sufficient detail so that when read in conjunction with cited references, all procedures can be repeated.
- 23 • Results: This section may be divided by subheadings. Footnotes should not be used and have to be
- 24 transferred into the main text.
- 25 • Discussion: This section may be divided by subheadings. Discussions should cover the key findings
- 26 of the study: discuss any prior art related to the subject so to place the novelty of the discovery in
- 27 the appropriate context; discuss the potential short-comings and limitations on their interpretations;
- 28 discuss their integration into the current understanding of the problem and how this advances the
- 29 current views; speculate on the future direction of the research and freely postulate theories that could
- 30 be tested in the future.

31 Please note that the Material and Methods section can be placed in any of the following ways: before

32 Results, before Discussion or after Discussion.

33 **Figure 1.** Enter the caption for your figure here. Repeat as necessary for each of your figures.

2.2 CLINICAL CASE STUDIES

34 For Clinical Case Studies the following sections are mandatory:

- 35 • Introduction: Include symptoms at presentation, physical exams and lab results.
- 36 • Background: This section may be divided by subheadings. Include history and review of similar cases.
- 37 • Results: This section may be divided by subheadings. Include diagnosis and treatment.
- 38 • Concluding Remarks

39 Please note that the Material and Methods section can be placed in any of the following ways: before

40 Results, before Discussion or after Discussion.

3 RESULTS

41 Frontiers requires figures to be submitted individually, in the same order as they are referred to in the

42 manuscript. Figures will then be automatically embedded at the bottom of the submitted manuscript.

43 Kindly ensure that each table and figure is mentioned in the text and in numerical order. Permission must

44 be obtained for use of copyrighted material from other sources (including the web). Please note that it

45 is compulsory to follow figure instructions. Figures which are not according to the guidelines will cause

46 substantial delay during the production process.

$$\sum x + y = Z \quad (1)$$

47 **Table1** shows the resolution requirements for the figures. The figures must be legible:

- 48 1. The smallest visible text is no less than 8 points in height, when viewed at actual size.
- 49 2. Solid lines are not broken up.
- 50 3. Image areas are not pixelated or stair stepped.
- 51 4. Text is legible and of high quality.
- 52 5. Any lines in the graphic are no smaller than 2 points width.

53 **Figure 2.** Enter the caption for your figure here. Repeat as necessary for each of your figures.

4 DISCUSSION

54 Text
55 Text Text Text Text. Additional Requirements:

4.1 CORRECTIONS

56 Minor corrections to published articles can be communicated to the Frontiers Production Office at
57 production.office@frontiersin.org. If you need to communicate important changes to an article please
58 submit a General Commentary. Submit the article with the title Erratum: Original Title of Article.

4.2 COMMENTARIES ON ARTICLES

59 At the beginning of your manuscript provide the citation of the article commented on.

4.3 FOCUSED REVIEWS

60 For Tier 2 invited Focused Reviews the sections Introduction, Material and Methods, Results, and
61 Discussion are recommended. In addition the authors must submit a short biography of the corresponding
62 author(s). This short biography has a maximum of 600 characters, including spaces.

63 A picture (5 x 5 cm, in *.tif or *.jpg, min 300 dpi) must be submitted along with the biography in
64 the manuscript and separately during figure upload. Focused Reviews highlight and explain key concepts
65 of your work. Please highlight a minimum of four and a maximum of ten key concepts in bold in your
66 manuscript and provide the definitions/explanations at the end of your manuscript under Key Concepts.
67 Each definition has a maximum of 400 characters, including spaces.

4.4 HUMAN SEARCH AND ANIMAL RESEARCH

68 All experiments on live vertebrates or higher invertebrates must be performed in accordance with
69 relevant institutional and national guidelines and regulations. In the manuscript, authors must identify
70 the committee approving the experiments and must confirm that all experiments conform to the relevant
71 regulatory standards. For manuscripts reporting experiments on human subjects, authors must identify the
72 committee approving the experiments and must also include a statement confirming that informed consent
73 was obtained from all subjects. In Original Research Articles and Clinical Trial Articles these statements
74 should appear in the Materials and Methods section.

Clinical trials should be registered in a public trials registry in order to become the object of a publication at Frontiers. Trials must be registered at or before the start of patient enrollment. A clinical trial is defined as “any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.” (www.who.int/ictcp/en). A list of acceptable registries can be found at www.who.int/ictcp/en and www.icmje.org.

Authors should provide relevant information relating to how the peptide/protein matches were undertaken, including methods used to process and analyze data, false discovery rates (FDR) for large-scale studies and threshold or cut-off rates for peptide and protein matches. Further information could include software used, mass spectrometer type, sequence database and version, number of sequences in database, processing methods, mass tolerances used for matching, variable/fixed modifications, allowable missed cleavages, etc.

Authors should provide as supplementary material information used to identify proteins and/or peptides. This should include information such as accession numbers, observed mass (m/z), charge, delta mass, matched mass, peptide/protein scores, peptide modification, miscleavages, peptide sequence, match rank, matched species (for cross species matching), number of peptide matches, ambiguous protein/peptide matches should be indicated, etc. For quantitative proteomics analyses authors should provide information to justify the statistical significance including biological replicates, statistical methods, estimates of uncertainty and the methods used for calculating error.

For peptide matches with biologically relevant post-translational modifications (PTM) and for any protein match that has occurred using a single mass spectrum, authors should include this information as raw data, annotated spectra or submit data to an online repository (recommended option). Authors are encouraged to submit raw or matched data and 2-DE images to public proteomics repositories. Submission codes and/or links to data should be provided within the manuscript.

Frontiers supports the policy of data sharing, and authors are advised to make freely available any materials and information described in their article, and any data relevant to the article (while not compromising confidentiality in the context of human-subject research) that may be reasonably requested by others for the purpose of academic and non-commercial research. In regards to deposition of data and data sharing through databases, Frontiers urges authors to comply with the current best practices within their discipline.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[illegible]

Funding: Text Text Text Text Text Text Text Text.

SUPPLEMENTAL DATA

109 Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text
110 Text Text Text Text Text Text.

REFERENCES

111 Author4, N. and Author5, N. (2013), Title of the article, *Frontiers in Neurorobotics*, 7, 25, doi:10.3389/
112 fnbot.2013.56789
113 LastName1, A., LastName2, A., and LastName2, A. (2013), Article title, *Frontiers in Neuroscience*, 30,
114 30, 10127–10134, doi:10.3389/fnins.2013.12345
115 OtherAuthor, N. and Coauthor, N. S. (2012), Article title, *Frontiers in Genetics*, 30, 49, 16417–16418,
116 doi:10.3389/fgene.2012.54321